Alerta

AN APPARATUS FOR STERILIZATION AND PURIFICATION AIR USING AN ELECTRON-BASED DISINFECTION MECHANISM

Resumen de: WO2026009244A1

The present invention relates to an electron-based apparatus for indoor air sterilization and purification, designed to neutralize airborne and surface-bound pathogens including viruses, bacteria, and fungi. The apparatus comprises a housing formed by an end cap (101), deco ring (102), top cover (103), bottom plate (108), and base ring (109), enclosing electron emitters mounted on a bobbin (104) and electrically connected via a 3 wire ring (105). A hypercharged electron cannon emits trillions of high-velocity, negatively charged electrons per second, which interact with viral spike proteins and microbial membranes, disrupting pathogen structure and infectivity without using filters, UV, or chemicals. A control box (106) and panel board (107) regulate emission parameters. The system supports plug-and-play operation, remote control, and requires no maintenance. Validated in virology and microbiology labs, it shows significant reductions in SARS-CoV-2 and other microbial loads. The apparatus is suitable for residential, commercial, and medical use, offering a safe and effective disinfection solution.

SARS-COV2 ANTIBODIES AND METHODS OF USE THEREOF

Resumen de: WO2026010909A1

The present disclosure is directed to antibodies and antigen binding fragments thereof, having improved binding specificity for coronaviruses, such as SARS-CoV-2, including neutralizing antibodies. Other embodiments contemplate using anti-CoV-S antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with coronaviruses or the S protein thereof and conditions where neutralization or inhibition of coronaviruses or the S protein thereof would be therapeutically beneficial.

VIRUS DETECTION VIA PROGRAMABLE TYPE III-A CRISPR-CAS SYSTEMS AND METHODS

Resumen de: US20260009092A1

Methods and systems, which use a reconstituted Type III-A CRISPR-Cas system, MORIARTY (Multipronged, One-pot, RNA Induced, Augmentable, Rapid, Test sYstem) for the detection of disease are provided herein. The methods and systems may be performed either without amplification or coupled to RNA transcription as one-pot reactions. The systems and methods herein may be highly sensitive and may be used to detect viruses, including SARS-CoV-2.

METHODS AND DEVICES FOR DETECTING A PATHOGEN AND ITS MOLECULAR COMPONENTS

Resumen de: US20260009789A1

Methods, systems and devices for detecting the presence of a pathogen, for example, a virus (e.g., SARS-CoV-2), or its molecular components, in health care-related samples and/or environmental samples are disclosed. An example system for improving detection of a pathogen includes biosensor device comprising a detection chip and at least one probe that specifically recognizes a pathogen, where the detection chip comprises a graphene field-effect transistor (FET) chip and the probe, which comprises an aptamer, specifically binds to a DNA, RNA, or protein associated with the pathogen.

NICLOSAMIDE FORMULATIONS AND METHODS OF USE

Resumen de: US20260007622A1

The present invention concerns compositions comprising at least one niclosamide compound, such as niclosamide or a pharmaceutically acceptable salt thereof, and at least one permeability enhancer, such as glycerol or dimethylpalmityl-ammonio propanesulfonate (PPS), and their use of such compositions as niclosamide agents. Advantageously, the niclosamide compound is capable of being transported across a Caco-2 cell membrane by at least 150% relative to the amount capable of being transported across the Caco-2 cell membrane in the absence of the permeability enhancer. Compositions, including oral dosage forms, and methods for delivering niclosamide compounds, such as for treatment or prevention of human coronavirus infections, are also provided.

NUTRACEUTICAL FORMULATIONS TO PREVENT, TREAT, AND INHIBIT EXCESS CYTOKINES, SARS-CoV-2 SPIKE PROTEINS, AND mRNA VACCINE SPIKE PROTEIN

Resumen de: US20260007711A1

Combinations of cannabinoids, vitamins, trace elements, bioactive components, bioflavonoid polyphenols, proteolytic enzymes, amino acids, and antioxidants which work independently and synergistically for the prevention, treatment, and inhibition of excess cytokines caused by the immune response to extreme viral and bacterial infections, including the inhibition of COVID-19, Rhinovirus and/or other virus spike proteins and mRNA vaccine spike proteins from attaching to body organ cells, penetrating cell membranes, and the replication of virus particles and spike proteins inside the cells. Inhibition of inflammation and prevention of long-term side effects, health issues (long-haulers), and disease caused by the SARS-COV-2 and its variants, Rhinovirus, other viruses, bacteria, and mRNA vaccines are provided by the nutraceutical compositions. Specific combinations of these compounds work synergistically to increase the efficacy of the independent nutraceuticals in treatment.

ROCK2 INHIBITORS FOR THE TREATMENT OF VIRAL INFECTIONS

Resumen de: US20260007673A1

The disclosure provides compositions and methods comprising selective inhibitors of Rho-associated coiled-coil kinase 2 (ROCK2) for use in the treatment of viral infections, particularly coronavirus infections such as SARS-CoV-2, and in the treatment of sequelae resulting from the viral infection, including sequelae resulting from coronavirus infection.

Effect of YEL002 on Conditions and Diseases

Resumen de: US20260007651A1

A preparation comprising the YEL002 compound as an active ingredient for the prevention or treatment of one or more diseases, and methods of using such preparations. The preparations may be a sublingual pill, an injection, dissolved in liquid, dissolved in oil, or any other preparation. The conditions or diseases indicated may be poisoning, radiation poisoning, chemotherapy poisoning, poor vision, peripheral artery disease, smoker's leg, diabetic feet, periodontal disease, varicose or spider veins, blood clots, COVID-19, long COVID, liver disease, symptoms caused by chemotherapy or radiation therapy, hair loss, cancer, inflammation-caused or inflammation-related diseases, autoimmune diseases, infections, and headaches including migraines.

Fiber optic sensor for testing for SARS-CoV-2 and method of making the sensor

Resumen de: PL449093A1

Przedmiotem zgłoszenia jest czujnik światłowodowy do badań na obecność SARS-CoV-2 oraz sposób wykonania tego czujnika. Czujnik światłowodowy do badań na obecność SARS-CoV-2, oparty na rezonansowym efekcie (LMR) oraz sposób wykonania tego czujnika. Obszarze czujnikowym (3) o długości od 5 do 100 mm znajdującym się na odsłoniętym rdzeniu (2) lub na bocznie pocienionym włóknie z pozostawieniem płaszcza resztkowego o grubości do 5 µm lub też na bocznie pocienionym włóknie z całkowicie pocienionym bocznie płaszczem (1) i częściowo do 20% pocienionym bocznie rdzeniem ma powłokę dielektryczną (4) o grubości co najmniej 10 nm. Część rzeczywista współczynnika załamania powłoki ma wartość większą niż wartość współczynnika załamania rdzenia włókna światłowodowego, a część urojona współczynnika załamania ma wartość bliską zeru lecz niezerową. Powłoka dielektryczna pokryta jest warstwą funkcjonalizacji (5) wykonanej metodą silanizacji i posiada unieruchomione na niej receptory (6) analitów pochodzących od SARS-CoV-2, w postaci przeciwciał skierowanych przeciwko jednemu z białek strukturalnych SARS-CoV-2 czyli przeciwciał anti-S albo przeciwciał anti-E albo przeciwciał anti-M albo przeciwciał anti-N.

2-(PIPERIDIN-3-YL)ISOINDOLE-1,3-DIONE ANALOGS AND USES THEREOF

Resumen de: WO2026006247A1

2-(Piperidin-3-yl)isoindole-1,3-dione analogs and uses thereof are disclosed. The compounds have a structure according to Formula I, or a stereoisomer or pharmaceutically acceptable salt, solvate, or hydrate thereof. The compounds may be useful for inhibiting TNF-α activity, TNF-α synthesis, interleukin-6 (IL-6) level, inflammation, or SARS-COV-2 virus. In some aspects, the compounds, or pharmaceutical compositions including the compounds, are administered to a subject a traumatic brain injury (TBI), an inflammatory disorder, a neurodegenerative disease, cancer, a viral infection, or any combination thereof.

COMPOUNDS AS NLRP3 INHIBITORS, AND COMPOSITIONS AND USES THEREOF

Resumen de: WO2026006510A1

NOD-like receptor protein 3 (NLRP3) inhibitors (NSIs) as anti-inflammatory agents are provided, as are methods of using the NSIs to inhibit inflammation and prevent or treat NRLP3 inflammasome dysregulation associated diseases and conditions, such as multiple sclerosis (MS), Alzheimer's disease (AD), traumatic brain injury (TBI), Parkinson's disease (PD), acute myocardial infarction (AMI), heart failure, gout, rheumatoid arthritis, COVID-19, diabetes, macular degeneration, and autoimmune/autoinflammatory diseases.

COMPOUNDS AS NLRP3 INHIBITORS AND COMPOSITIONS AND USES THEREOF

Resumen de: WO2026006505A1

NSIs with anti-inflammatory activity are provided, as are methods of using the NSIs to inhibit inflammation and prevent or treat diseases and conditions associated with inflammation, such as multiple sclerosis (MS), Alzheimer's disease (AD), traumatic brain injury (TBI), Parkinson's disease (PD), acute myocardial infarction (AMI), heart failure, gout, rheumatoid arthritis, COVID- 19, diabetes, macular degeneration, or an autoimmune or autoinflammatory disease.

COMPOUNDS AS NLRP3 PET RADIOTRACERS AND COMPOSITIONS AND USES THEREOF

Resumen de: WO2026006503A1

NLRP3 PET radiotracers are provided, as are methods of using the NLRP3 PET radiotracers to image and/or diagnose diseases and conditions associated with inflammation, such as multiple sclerosis (MS), Alzheimer's disease (AD), traumatic brain injury (TBI), Parkinson's disease (PD), acute myocardial infarction (AMI), heart failure, gout, rheumatoid arthritis, COVID- 19, diabetes, macular degeneration, and autoimmune/autoinflammatory diseases.

PREVENTION AND TREATMENT OF CORONAVIRUS INFECTION

Resumen de: US20260000668A1

Provided herein are compositions comprising one or more diphenyl compounds, such as ANAVEX 1066, or its metabolites, or isomers, or salts, for use in treating symptoms of, or preventing an infection by a coronavirus, particularly an infection caused by a SARS-COV-2 virus.

ANTIGEN SPECIFIC IMMUNOTHERAPY FOR COVID-19 FUSION PROTEINS AND METHODS OF USE

Resumen de: US20260000752A1

The present disclosure provides recombinantly manufactured fusion proteins comprising a SARS-CoV-2 Receptor Binding Domain (SARS-CoV-2-RBD) fragment or an analog thereof linked to a human Fc fragment for use in relation to the 2019 Novel Coronavirus (COVID-19). Embodiments include the administration of the fusion proteins to patients that have recovered from COVID-19 as a booster vaccination, to antibody naïve patients to produce antibodies to the SARS-CoV-2 virus to enable the patients to become convalescent plasma donors, to patients who have been infected by the SARS-CoV-2 virus and have contracted COVID-19 in order to limit the scope of the infection and ameliorate the disease, and as a prophylactic COVID-19 vaccine. Exemplary Fc fusion proteins and pharmaceutical formulations of exemplary Fc fusion proteins are provided, in addition to methods of use and preparation.

SARS-COV-2 NSP14 METHYLTRANSFERASE INHIBITORS

Resumen de: US20260000698A1

Disclosed herein are compounds of formulaor pharmaceutically acceptable salts thereof, and methods of using the same for treating a viral infection or inhibiting replication of a virus.

AN EPITOPE ORIGINATING FROM SARS-COV-2 N PROTEIN, AN ANTIGEN CONTAINING THE EPITOPE, USES THEREOF AND A METHOD FOR DETECTING DISEASE CAUSED BY CORONAVIRUS

Resumen de: WO2024177525A2

Epitopes originating from SARS-CoV-2 N protein, vaccine antigens specific for SARS-CoV-2 containing the epitopes useful in the treatment or prevention of disease caused by coronavirus as well as a method for detecting disease caused by coronavirus, in particular COVID-19, especially with an acute course, are disclosed.

SARS-COV-2 NEUTRALIZING ANTIBODIES

Resumen de: TW202440626A

The present invention relates to antibodies or antigen-binding fragments thereof against SARS- related coronavirus, pharmaceutical compositions comprising such antibodies or antigen-binding fragments thereof, kits comprising such antibodies or antigen-binding fragments thereof, and the antibodies or antigen-binding fragments thereof, the pharmaceutical compositions and the kits for use as a medicament, and in the treatment or prevention of a disease caused by SARS-related coronavirus. The present invention further relates to methods of treating, preventing or reducing the severity of an infection with a SARS-related coronavirus, and to nucleic acids encoding such antibodies or antigen-binding fragments thereof, expression vectors comprising such nucleic acids, host cells comprising such nucleic acids or expression vectors, and methods for the production of such antibodies or antigen-binding fragments thereof.

Medicated diet composition for treating heat cough, and preparation method therefor and use thereof

Resumen de: GB2642116A

A medicated diet composition for treating a heat cough, prepared from the raw materials in the following parts by mass: 50-100 parts of kumquat, 30-50 parts of Eleocharis dulcis, 5-10 parts of Glehniae radix and 5-10 parts of Platycodonis radix. The medicated diet composition can improve the symptoms of a heat cough of a SARS-CoV-2 infection.

COMPOSITION FOR PREVENTING OR TREATING CHEMOSENSORY DISORDER

Nº publicación: EP4670725A1 31/12/2025

Solicitante:

UNIV NAGASAKI [JP]
KIRIN HOLDINGS KK [JP]
NAGASAKI UNIVERSITY,
KIRIN HOLDINGS KABUSHIKI KAISHA

Resumen de: EP4670725A1

The purpose of the present invention is to provide a composition for preventing or treating a chemosensory disorder. The present invention provides a composition for preventing or treating a chemosensory disorder, comprising a lactic acid bacterium. The chemosensory disorder can be a chemosensory disorder that occurs after SARS-CoV-2 viral infection. The present invention is advantageous in that lactic acid bacteria can be used as a functional ingredient that imparts a preventive or therapeutic effect against a chemosensory disorder, and a pharmaceutical product or a food product that is safe for mammals including humans can be provided.